Lymphocyte antigen 96: A new potential biomarker and immune target in Parkinson's disease
Experimental Gerontology · 2024-06 · 190 · 112415
DOI: 10.1016/j.exger.2024.112415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Gerontology, 2024-06. Verfasst von Haoran Peng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, People's Hospital of Henan University, Zhengzhou 450003, Henan, China; Department of Neurology, Henan Provincial People's Ho…. Hauptthemen laut MEDLINE: Biomarkers, Parkinson Disease, Lymphocyte Antigen 96. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Lymphocyte antigen 96 (LY96) plays an important role in innate immunity and has been reported to be associated with various neurological diseases. However, its role in Parkinson's disease (PD) remains unclear. METHODS: Transcriptome data from a total of 49 patients with PD and 34 healthy controls were downloaded from the Gene Expression Omnibus (GEO) database to analyse the expression pattern of LY96 and its relationship with gene function and immune-related markers. In addition, peripheral blood samples were collected from clinical patients to validate LY96 mRNA expression levels. Finally, an in vitro cell model of PD based on highly differentiated SH-SY5Y cells was constructed, with small interfering RNA-silenced LY96 expression, and LY96 mRNA level, cell viability, flow cytometry, and mitochondrial membrane potential assays were performed. RESULTS: The results of the analyses of the GEO database and clinical samples revealed significantly abnormally high LY96 expression in patients with PD compared with healthy controls. The results of cell experiments showed that inhibiting LY96 expression alleviated adverse cellular effects by increasing cell viability, reducing apoptosis, and reducing oxidative stress. Gene set enrichment analysis showed that LY96 was positively correlated with T1 helper cells, T2 helper cells, neutrophils, natural killer T cells, myeloid-derived suppressor cells, macrophages, and activated CD4 cells, and may participate in PD through natural killer cell-mediated cytotoxicity pathways and extracellular matrix receptor interaction pathways. CONCLUSION: These findings suggested that LY96 might be a novel potential biomarker for PD, and offer insights into its immunoregulatory role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, People's Hospital of Henan University, Zhengzhou 450003, Henan, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou 450003, Henan, China.
- Department of Neurology, Henan Provincial People's Hospital, Zhengzhou 450003, Henan, China; Department of Neurology, People's Hospital of Zhengzhou University, Zhengzhou 450003, Henan, China.
- Department of Neurology, People's Hospital of Henan University, Zhengzhou 450003, Henan, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou 450003, Henan, China; Department of Neurology, Peopl…
Zitieren
APA
Peng, H., Wu, L., Chen, S., Wu, S., Shi, X., Ma, J., Yang, H., & Li, X. (2024). Lymphocyte antigen 96: A new potential biomarker and immune target in Parkinson's disease. Experimental Gerontology, 190, 112415. https://doi.org/10.1016/j.exger.2024.112415
Vancouver
Peng H, Wu L, Chen S, Wu S, Shi X, Ma J, et al. Lymphocyte antigen 96: A new potential biomarker and immune target in Parkinson's disease. Experimental Gerontology. 2024;190:112415. doi:10.1016/j.exger.2024.112415
BibTeX
@article{Peng2024,
author = {Peng, Haoran and Wu, Longyu and Chen, Siyuan and Wu, Shaopu and Shi, Xiaoxue and Ma, Jianjun and Yang, Hongqi and Li, Xue},
title = {Lymphocyte antigen 96: A new potential biomarker and immune target in Parkinson's disease},
journal = {Experimental Gerontology},
year = {2024},
volume = {190},
pages = {112415},
doi = {10.1016/j.exger.2024.112415}
}
EUVIMED